Cardiorenal syndrome is a complex interaction between the cardiovascular and renal systems, often resulting from heart failure (HF) or renal disease. It affects over 5 million Americans, with nearly half rehospitalized for acute decompensated heart failure (ADHF). In the U.S., the prevalence of HF is 2.3%, with similar rates in West Sumatra. HF is often linked to subendocardial ischemia or renal impairment. Studies show that 41-55% of HF patients are rehospitalized within six months. The syndrome is defined variably depending on clinical expertise, with some viewing it as HF associated with renal disease, and others as a renal condition in the context of cardiovascular disease. The syndrome involves a cycle of neurohormonal activation, leading to interrelated cardiac and renal responses. The sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS) play key roles, with increased SNS activity raising blood pressure and RAAS stimulating sodium and fluid retention, increasing cardiac preload. Chronic activation can lead to a vicious cycle of worsening cardiorenal function. Clinical manifestations include neurohormonal imbalances, with excess vasodilation or vasoconstriction affecting renal and cardiac function. Hypoperfusion can result from conditions like hypotension, renal arterial disease, or dehydration. Comorbidities such as diabetes, hypertension, and peripheral vascular disease are common in chronic kidney disease (CKD). Creatinine levels and glomerular filtration rate (GFR) are important predictors of mortality in HF patients. ACE inhibitors are a cornerstone of treatment for left ventricular dysfunction but can cause creatinine and potassium elevations. Continued use is recommended if renal function does not worsen. Diuretics can worsen renal function, while positive inotropic agents and vasodilators may improve hemodynamics. Treatment targets include diuretics, ultrafiltration, inflammation control, and anti-RAAS therapy. The UNLOAD trial highlights the importance of early ultrafiltration and RAAS inhibitors in improving outcomes. Effective management requires balancing cardiac and renal function to prevent progression and mortality.Cardiorenal syndrome is a complex interaction between the cardiovascular and renal systems, often resulting from heart failure (HF) or renal disease. It affects over 5 million Americans, with nearly half rehospitalized for acute decompensated heart failure (ADHF). In the U.S., the prevalence of HF is 2.3%, with similar rates in West Sumatra. HF is often linked to subendocardial ischemia or renal impairment. Studies show that 41-55% of HF patients are rehospitalized within six months. The syndrome is defined variably depending on clinical expertise, with some viewing it as HF associated with renal disease, and others as a renal condition in the context of cardiovascular disease. The syndrome involves a cycle of neurohormonal activation, leading to interrelated cardiac and renal responses. The sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS) play key roles, with increased SNS activity raising blood pressure and RAAS stimulating sodium and fluid retention, increasing cardiac preload. Chronic activation can lead to a vicious cycle of worsening cardiorenal function. Clinical manifestations include neurohormonal imbalances, with excess vasodilation or vasoconstriction affecting renal and cardiac function. Hypoperfusion can result from conditions like hypotension, renal arterial disease, or dehydration. Comorbidities such as diabetes, hypertension, and peripheral vascular disease are common in chronic kidney disease (CKD). Creatinine levels and glomerular filtration rate (GFR) are important predictors of mortality in HF patients. ACE inhibitors are a cornerstone of treatment for left ventricular dysfunction but can cause creatinine and potassium elevations. Continued use is recommended if renal function does not worsen. Diuretics can worsen renal function, while positive inotropic agents and vasodilators may improve hemodynamics. Treatment targets include diuretics, ultrafiltration, inflammation control, and anti-RAAS therapy. The UNLOAD trial highlights the importance of early ultrafiltration and RAAS inhibitors in improving outcomes. Effective management requires balancing cardiac and renal function to prevent progression and mortality.